Pamidronate Disodium Precautions, Details, Emergency, warnings, Fda, api, Active Pharmaceutical Ingredients, Symptoms, Exporters, Pamidronate Disodium, Causes, Health Centres, Importers, Molecular Formula C3H9NNa2O7P2, Molecular Weight 279.03, CAS Registry Number 109552-15-0, Generic Products, bulk drugs, Raw Material Exporters, Research, Taj Pharmaceuticals LTd.

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Pharma industries Taj API

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Pamidronate Disodium Manufacturers in India Suppliers Pamidronate Disodium Exporters Distributors Pamidronate Disodium api active pharmaceuticals ingredients Pamidronate Disodium manufacturers Side Effects bulk drugs raw material Pamidronate Disodium companies Side Effects Importers Pamidronate Disodium Pamidronate Disodium Exporters Pamidronate Disodium exporters FDA Pamidronate Disodium DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Pamidronate Disodium manufacturing pharmaceutical drugs pharmaceutical intermediates Pamidronate Disodium pharmaceutical chemicals pharmaceutical raw materials Pamidronate Disodium active pharmaceutical ingredients Pamidronate Disodium committee active pharmaceutical ingredients manufacturer Pamidronate Disodium Active Pharmaceutical Ingredients manufacturer Pamidronate Disodium exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Pamidronate Disodium, Pamidronate Disodium manufacturer India, Pamidronate Disodium product, Pamidronate Disodium products, Api preparation, Certificate of Analysis API manufacturer product, Pamidronate Disodium anti ulcer product, Certificate of Origin COA Pamidronate Disodium COS Pamidronate Disodium, pharmaceutical generic, pharmaceutical drug, medical, Pamidronate Disodium pharma healthcare, pharma patents, contract MSDS manufacturing Trader Pamidronate Disodium pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Pamidronate Disodium expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Pamidronate Disodium DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Pamidronate Disodium ingredients, api, HIV Pamidronate Disodium, tablets, capsules, syrup & protein Pamidronate Disodium powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Pamidronate Disodium gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Pamidronate Disodium WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

pharmaceuticals

HOME >> API >> API List 3 >> Pamidronate Disodium >> Precautions

PRECAUTIONS
Pamidronate Disodium CAS Number 109552-15-0

Osteonecrosis of the jaw (ONJ) has been reported predominantly in cancer patients treated with intravenous bisphosphonates, including . Many of these patients were also receiving chemotherapy and corticosteroids which may be risk factors for ONJ. Postmarketing experience and the literature suggest a greater frequency of reports of ONJ based on tumor type (advanced breast cancer, multiple myeloma), and dental status (dental extraction, periodontal disease, local trauma including poorly fitting dentures). Many reports of ONJ involved patients with signs of local infection including osteomyelitis.

Cancer patients should maintain good oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates.

While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop ONJ while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.

Nursing Mothers

It is not known whether is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when is administered to a nursing woman.
Pediatric Use

Safety and effectiveness of in pediatric patients have not been established.

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE

SIDE EFFECTS

PRECAUTIONS >>

INTERACTION

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.